WHO to review its interim guidance on the use of delamanid in the treatment of multidrug-resistant TB following the release of Phase III clinical trial results

The World Health Organization (WHO) has started preparations for a rapid review of its interim guidance on the use of delamanid in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB). This follows the release of the phase III randomised control trial results by Otsuka Pharmaceutical at the 48th Union World Conference on Lung Health on 13 October.

To read the full announcement, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By World Health Organization

Published: Oct. 28, 2017, 1:49 p.m.

Last updated: Oct. 28, 2017, 1:49 p.m.

Print Share